1. Deng J., Zhu X., Chen Z. et al. A review of food-drug interactions on oral drug absorption // Drugs. 2017. Vol. 77. P. 1833-1855. DOI: 10.1007/s40265-017-0832-z
2. Martinez M. N., Amidon G. L. A mechanistic approach to understandingthe factors affecting drug absorption: a review of fundamentals // J Clin Pharmacol. 2002. Vol. 42. P. 620-643. DOI: 10.1177/00970002042006005
3. Maddox A., Horowitz M., Wishart J., Collins P. Gastric and oesophageal emptying in obesity // Scand J Gastroenterol. 1989. Vol. 24. P. 593-598. DOI: 10.3109/00365528909093095
4. Jackson S. J., Leahy F. E., McGowan A. A. et al. Delayed gastric emptying in the obese: an assessment using the noninvasive (13)C-octanoic acid breath test // Diabetes Obes Metab. 2004. Vol. 6. P. 264-270. DOI: 10.1111/j.1462-8902.2004.0344.x
5. Janson B., Thursky K. Dosing of antibiotics in obesity // Curr Opin Infect Dis 2012. Vol. 25. P. 634-649. DOI: 10.1097/QCO.0b013e328359a4c1
6. Morrish G. A., Pai M. P., Green B. The effects of obesity on drug pharmacokinetics in humans // Expert Opin Drug Metab Toxicol. 2011. Vol. 7. P. 697-706. DOI: 10.1517/17425255.2011.570331
7. Hanley M. J., Abernethy D. R., Greenblatt D. J. Effect of obesity on the pharmacokinetics of drugs in humans // Clin Pharmacokinet. 2010. Vol. 49. P. 71-87. DOI: 10.2165/11318100-000000000-00000
8. Alobaid A. S., Hites M., Lipman J. et al. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review // Int J Antimicrob Agents. 2016. Vol. 47. P. 259-268. DOI: 10.1016/j.ijantimicag.2016.01.009
9. Poirier P., Giles T. D., Bray G. A. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss // Circulation. 2006. Vol. 113. P. 898-918. DOI: 10.1161/CIRCULATIONAHA.106.171016
10. Rossi M., Nannipieri M., Anselmino M. et al. Subcutaneous adipose tissue blood flow and vasomotion in morbidly obese patients: long term effect of gastric bypass surgery // Clin Hemorheol Microcirc. 2012. Vol. 51. P. 159-167. DOI: 10.3233/CH-2011-1517
11. Suh B., Craig W. A., England A. C., Elliott R. L. Effect of free fatty acids on protein binding of antimicrobial agents // J Infect Dis. 1981. Vol. 143. P. 609-616. DOI: 10.1093/infdis/143.4.609
12. Polso A. K., Lassiter J. L., Nagel J. L. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review // J Clin Pharm Ther. 2014. Vol. 39. P. 584-608. DOI: 10.1111/jcpt.12200
13. Morita K., Yamaji A. Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum α1-acid glycoprotein levels // Ther Drug Monit. 1995. Vol. 17. P. 107-112. DOI: 10.1097/00007691-199504000-00001
14. Zokufa H. Z., Solem L. D., Rodvold K. A. et al. 1989. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries // J Burn Care Rehabil. 1989. Vol. 10. P. 425-428. DOI: 10.1097/00004630-198909000-00010
15. Smit C., De Hoogd S., Brüggemann R. J. M., Knibbe C. A. J. 2018. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters // Expert Opin Drug Metab Toxicol. 2018. Vol. 14. P. 275-285. DOI: 10.1080/17425255.2018.1440287
16. Kotlyar M., Carson S. W. Effects of obesity on the cytochrome P450 enzyme system // Int J Clin Pharmacol Ther. 1999. Vol. 37. P. 8-19.
17. Griffin K. A., Kramer H., Bidani A. K. Adverse renal consequences of obesity // Am J Physiol Renal Physiol. 2008. Vol. 294. P. F685-96. DOI: 10.1152/ajprenal.00324.2007
18. Meng L., Mui E., Ha D. R. et al. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update // Pharmacotherapy. 2023. Vol. 43. P. 226-246. DOI: 10.1002/phar.2769 EDN: FPMBPG
19. Castro-Balado A., Varela-Rey I., Mejuto B. et al. Updated antimicrobial dosing recommendations for obese patients // Antimicrob Agents Chemother. 2024. Vol. 68, № 5. P. e0171923. 10.1128/aac.01719-23. PMID: 38526051; PMCID: PMC11064535. DOI: 10.1128/aac.01719-23.;PMCID PMID: 38526051
20. Velissaris D., Karamouzos V., Marangos M., et al. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review // J Clin Med Res. 2014. Vol. 6. P. 227-233. DOI: 10.14740/jocmr1858w
21. Traynor A. M., Nafziger A. N., Bertino J. S. 1995. Aminoglycoside dosing weight correction factors for patients of various body sizes // Antimicrob Agents Chemother. 1995. Vol. 39. P. 545-548. DOI: 10.1128/AAC.39.2.545
22. Bergan T. Pharmacokinetics of beta-lactam antibiotics // Scand J Infect Dis Suppl. 1984. Vol. 42. P. 83-98. PMID. P. 6597564.
23. Hites M., Taccone F. S., Wolff F. et al. Broad-spectrum β-lactams in obese non-critically ill patients // Nutr Diabetes. 2014. Vol. 4, № 6. P. e119. 10.1038/nutd.2014.15. PMID: 24956136; PMCID: PMC4079925. DOI: 10.1038/nutd.2014.15.;PMCID PMID: 24956136
24. Kanbay M., Copur S., Bakir C. N. et al. Glomerular hyperfiltration as a therapeutic target for CKD // Nephrol Dial Transplant. 2024. Vol. 39, № 8. P. 1228-1238. PMID: 38308513. DOI: 10.1093/ndt/gfae027. PMID: 38308513
25. Roberts J. A., Croom K., Adomakoh N. Continuous infusion of beta lactam antibiotics: narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy // Expert Rev Anti Infect Ther. 2023. Vol. 21. P. 375-385. DOI: 10.1080/14787210.2023.2184347
26. Клинические рекомендации: Внебольничная пневмония у взрослых. URL: https://cr.minzdrav.gov.ru/preview-cr/654_2 (дата обращения: 29.01.2025).
27. Клинические рекомендации: Сепсис (у взрослых). Электронный доступ: https://cr.minzdrav.gov.ru/previewcr/898_1 (дата обращения: 29.01.2025).
28. Клинические рекомендации: Острый пиелонефрит. Электронный доступ: https://cr.minzdrav.gov.ru/previewcr/9_3 (дата обращения: 29.01.2025).
29. Van Rhee K. P., Smit C., Wasmann R. E. et al. Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study // Clin Pharmacokinet. 2022. Vol. 61, № 8. P. 1167-1175. 10.1007/s40262-022-01130-5. PMID: 35641862; PMCID: PMC9349153. DOI: 10.1007/s40262-022-01130-5.;PMCID PMID: 35641862
30. Allard S., Kinzig M., Boivin G. et al. Intravenous ciprofloxacin disposition in obesity // Clin Pharmacol Ther. 1993. Vol. 54, № 4. P. 368-73. PMID: 8222478. DOI: 10.1038/clpt.1993.162. PMID: 8222478
31. Hollenstein U. M., Brunner M., Schmid R. et al Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing // Int J Obes Relat Metab Disord. 2001. Vol. 25. P. 354-8.
32. Hopkins M. K., Tewari S., Yao M. et al. Standard-dose azithromycin in class III obese patients undergoing unscheduled cesarean delivery // Am J Perinatol. 2024. Vol. 41, № S 01. P. e2645-e2650. DOI: 10.1055/a-2135-7084
33. Peyriere H., Makinson A., Marchandin H., Reynes J. Doxycycline in the management of sexually transmitted infections // J Antimicrob Chemother. 2018. Vol. 73. P. 553-563. DOI: 10.1093/jac/dkx420
34. Bouazza N., Pestre V., Jullien V. et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis // Br J Clin Pharmacol. 2012. Vol. 74, № 6. P. 971-7. 10.1111/j.1365-2125.2012.04292.x. PMID: 22486719; PMCID: PMC3522810. DOI: 10.1111/j.1365-2125.2012.04292.x.;PMCID PMID: 22486719
35. Nicholas P., Meyers B. R., Levy R. N., Hirschman S. Z. Concentration of clindamycin in human bone // Antimicrob Agents Chemother. 1975. Vol. 8, № 2. P. 220-1. 10.1128/AAC.8.2.220. PMID: 1180546; PMCID: PMC429291. DOI: 10.1128/AAC.8.2.220.;PMCID PMID: 1180546
36. Nikolos P., Osorio J., Mohrien K., Rose C. Pharmacokinetics of linezolid for methicillin-resistant Staphylococcus aureus pneumonia in an adult receiving extracorporeal membrane oxygenation // Am J Health Syst Pharm. 2020. Vol. 77, № 11. P. 877-881. PMID: 32426841. DOI: 10.1093/ajhp/zxaa066. PMID: 32426841
37. Heidari S., Khalili H. Linezolid pharmacokinetics: a systematic review for the best clinical practice // Eur J Clin Pharmacol. 2023. Vol. 79. P. 195-206. DOI: 10.1007/s00228-022-03446-4
38. Белобородов В. Б., Голованов О.В., Гусаров В.Г., и др. Обновленные методические рекомендации “Диагностика и антимикробная терапия инфекций, вызванных полирезистентными штаммами микроорганизмов”. 2022. URL: https://www.antibiotic.ru/files/334/mr-abt.pdf (дата обращения: 19.03.24).
39. Polso A. K., Lassiter J. L., Nagel J. L. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review // J Clin Pharm Ther. 2014. Vol. 39. P. 584-608. DOI: 10.1111/jcpt.12200
40. Garrett E. R., Süverkrup R. S., Eberst K. et al. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese // Biopharm Drug Dispos. 1981. Vol. 2. P. 329-365. DOI: 10.1002/bdd.2510020405
41. Hall R. G., Pasipanodya J. G., Meek C. et al. Fractal geometry-based decrease in trimethoprim-sulfamethoxa zole concentrations in overweight and obese people // CPT Pharmaco metrics Syst Pharmacol. 2016. Vol. 5. P. 674-681. DOI: 10.1002/psp4.12146
42. Dorn C., Petroff D., Neumann N. et al. Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial // J Antimicrob Chemother. 2019. Vol. 74. P. 2335-2340. DOI: 10.1093/jac/dkz203
43. Busse D., Simon P., Petroff D. et al. 2022. High-dosage fosfomycin results in adequate plasma and target-site exposure in morbidly obese and nonobese nonhyperfiltration patients // Antimicrob Agents Chemother. 2022. Vol. 66, № 6. P. e0230221. DOI: 10.1128/aac.02302-21
44. Crass R. L., Dunn R., Hong J. et al. Dosing vancomycin in the super obese: less is more // J Antimicrob Chemother. 2018. Vol. 73. P. 3081-3086. DOI: 10.1093/jac/dky310
45. Monteiro J. F., Hahn S. R., Gonçalves J., Fresco P. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations // Pharmacol Res Perspect. 2018. Vol. 6. P. e00420. DOI: 10.1002/prp2.420
46. Rybak M. J., Le J., Lodise T. P. et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists // Am J Health Syst Pharm. 2020. Vol. 77. P. 835-864. DOI: 10.1093/ajhp/zxaa036
47. Elrggal M. E., Haseeb A., AlGethamy M. et al. Dose optimization of vancomycin in obese patients: a systematic review // Front Pharmacol. 2023. Vol. 14. P. 965284. DOI: 10.3389/fphar.2023.965284
48. Zhang T., Smit C., Sherwin C. M. T. et al. Vancomycin clearance in obese adults is not predictive of clearance in obese adolescents // Clin Pharmacokinet. 2023. Vol. 62. P. 749-759. DOI: 10.1007/s40262-023-01227-5
49. Soule A. F., Green S. B., Blanchette L. M. Clinical efficacy of 12-h metronidazole dosing regimens in patients with anaerobic or mixed anaerobic infections // Ther Adv Infect Dis. 2018. Vol. 5. P. 57-62. DOI: 10.1177/2049936118766462
50. Martin C., Auboyer C., Boisson M. et al. Antibiopro phylaxis in surgery and interventional medicine (adult patients). Update 2017 // Anaesth Crit Care Pain Med. 2019. Vol. 38. P. 549-562. DOI: 10.1016/j.accpm.2019.02.017
51. Nation R. L., Garonzik S. M., Thamlikitkul V. et al. Dosing guidance for intravenous colistin in critically-ill patients // Clin Infect Dis. 2017. Vol. 64. P. 565-571. DOI: 10.1093/cid/ciw839
52. Tsuji B. T., Pogue J. M., Zavascki A. P. et al. Interna tional consensus guidelines for the optimal use of the polymyxins. P. endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP) // Pharmacotherapy. 2019. Vol. 39. P. 10-39.
53. WHO (2020), Obesity and overweight. URL: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (дата обращения: 29.01.2025).
54. Ожирение: этиология, патогенез, клинические аспекты. Под редакцией И. И. Дедова, Г. А. Мельниченко. Москва, Медицинское информационное агентство, 2004. P. 16-21.
55. OECD (2021), Overweight or obese population (indicator). 10.1787/86583552-en (accessed: 28.08.2021).
